Sanders Morris Harris LLC Buys 1,549 Shares of Merck & Co., Inc. (NYSE:MRK)

Sanders Morris Harris LLC grew its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 34.3% during the first quarter, Holdings Channel.com reports. The fund owned 6,066 shares of the company’s stock after purchasing an additional 1,549 shares during the quarter. Sanders Morris Harris LLC’s holdings in Merck & Co., Inc. were worth $800,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Algert Global LLC purchased a new stake in Merck & Co., Inc. during the third quarter valued at approximately $454,000. Certified Advisory Corp lifted its position in Merck & Co., Inc. by 256.6% during the third quarter. Certified Advisory Corp now owns 21,928 shares of the company’s stock valued at $2,257,000 after acquiring an additional 15,779 shares during the last quarter. Brasada Capital Management LP lifted its position in Merck & Co., Inc. by 11.5% during the third quarter. Brasada Capital Management LP now owns 18,734 shares of the company’s stock valued at $1,958,000 after acquiring an additional 1,936 shares during the last quarter. Consolidated Portfolio Review Corp lifted its position in Merck & Co., Inc. by 3.6% during the third quarter. Consolidated Portfolio Review Corp now owns 4,451 shares of the company’s stock valued at $458,000 after acquiring an additional 154 shares during the last quarter. Finally, GSB Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 0.6% in the third quarter. GSB Wealth Management LLC now owns 37,504 shares of the company’s stock worth $3,861,000 after buying an additional 222 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Wells Fargo & Company raised their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Merck & Co., Inc. in a report on Tuesday. Truist Financial raised their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target for the company. in a report on Monday, March 11th. Finally, Berenberg Bank raised their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Check Out Our Latest Stock Report on Merck & Co., Inc.

Merck & Co., Inc. Trading Up 0.8 %

MRK stock traded up $1.05 during trading on Friday, reaching $130.72. 17,182,704 shares of the stock were exchanged, compared to its average volume of 7,458,603. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. The business has a 50 day moving average price of $128.85 and a 200-day moving average price of $123.37. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $133.10. The firm has a market capitalization of $331.09 billion, a price-to-earnings ratio of 145.24, a P/E/G ratio of 2.50 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.21 billion. During the same period in the previous year, the firm earned $1.40 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, research analysts predict that Merck & Co., Inc. will post 8.64 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Stockholders of record on Monday, June 17th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.22%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.